RANI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RANI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Rani Therapeutics Holdings's enterprise value is $61.29 Mil. Rani Therapeutics Holdings's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil. Therefore, Rani Therapeutics Holdings's EV-to-Revenue for today is .
The historical rank and industry rank for Rani Therapeutics Holdings's EV-to-Revenue or its related term are showing as below:
During the past 5 years, the highest EV-to-Revenue of Rani Therapeutics Holdings was 209.30. The lowest was -6.21. And the median was 37.03.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-12-13), Rani Therapeutics Holdings's stock price is $1.66. Rani Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00. Therefore, Rani Therapeutics Holdings's PS Ratio for today is .
The historical data trend for Rani Therapeutics Holdings's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rani Therapeutics Holdings Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
EV-to-Revenue | - | - | 102.68 | - | - |
Rani Therapeutics Holdings Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EV-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Rani Therapeutics Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Rani Therapeutics Holdings's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Rani Therapeutics Holdings's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 61.290 | / | 0 | |
= |
Rani Therapeutics Holdings's current Enterprise Value is $61.29 Mil.
Rani Therapeutics Holdings's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rani Therapeutics Holdings (NAS:RANI) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Rani Therapeutics Holdings's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 1.66 | / | 0 | |
= |
Rani Therapeutics Holdings's share price for today is $1.66.
Rani Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Rani Therapeutics Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
South Cone Investments Limited Partnership | 10 percent owner | AVENIDA PRESIDENTE RIESCO 5711 OFICINA 1, LAS CONDES, SANTIAGO F3 7550000 |
Talat Imran | director, officer: CEO | C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131 |
Quiroga Cortes Isidoro Alfonso | 10 percent owner | 9020 N CAPITAL OF TEXAS HWY, SUITE I-260, AUSTIN TX 78759 |
Jean Luc Butel | director | ONE BAXTER PARKWAY, DEERFIELD IL 60015 |
Maulik Nanavaty | director | BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234 |
Kate Mckinley | officer: CHIEF BUSINESS OFFICER | C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131 |
Svai S Sanford | officer: CFO | C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE CA 95131 |
Eric Groen | officer: General Counsel | C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131 |
Mir Hashim | officer: Chief Scientific Officer | C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131 |
South Lake One Llc | 10 percent owner | 250 WEST 55TH STREET, NEW YORK NY 10019 |
Aequanimitas Limited Partnership | 10 percent owner | LEONEL AGUIRRE 1830, UNIT 101, MONTEVIDEO X3 11500 |
Mir A Imran | director | |
Andrew Farquharson | director | C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131 |
Laureen Debuono | director | |
Lisa Ann Rometty | director | C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131 |
From GuruFocus
By Marketwired • 06-24-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 10-08-2024
By Marketwired • 10-17-2024
By GuruFocus Research • 03-21-2024
By Marketwired • 05-14-2024
By Marketwired • 05-06-2024
By Marketwired • 10-12-2023
By GuruFocus Research • 02-08-2024
By Marketwired • 11-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.